15 completed, 5 terminated, 4 withdrawn, 2 active not recruiting. 17 Phase 2, 4 Not applicable, 4 Phase 3, 2 Phase 1.
Follow Sulindac: new trials by email Literature Review of Sulindac trials Research Report on Sulindac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40 Sulindac (HLX-0201), dose strength 1, Sulindac (HLX-0201), dose strength 2, Placebo - Fragile X Syndrome | Phase 2 | Withdrawn | Healx Limited | 2022-05-25 | 2022-12-08 | |
| Sulindac and Breast Density in Women at Risk of Developing Breast Cancer Sulindac Pill, Placebo - Breast Cancer | Phase 2 | Completed | Alison Stopeck | 61 | 2020-11-20 | 2026-07-17 |
| The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) Sulindac 400 MG, Placebo - IPMN, IPMN, Pancreatic | Phase 2 | Active not recruiting | Duke University | 100 | 2020-07-10 | 2026-09-08 |
| Urinary Biomarker Study With Sulindac and Difluoromethylornithine difluoromethylornithine, Sulindac - Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms | Phase 2 | Withdrawn | Cancer Prevention Pharmaceuticals, Inc. | 2014-03-01 | 2014-07-30 | |
| Sulindac for Patients With AML Cytarabine, Sulindac - Acute Myeloid Leukemia | Phase 2 | Withdrawn | Massachusetts General Hospital | 2014-01-01 | 2017-02-17 | |
| Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine, Eflornithine Placebo, Sulindac 150 MG - Familial Adenomatous Polyposis | Phase 3 | Completed | Cancer Prevention Pharmaceuticals, Inc. | 171 | 2013-10-01 | 2021-06-08 |
| S0820, Adenoma and Second Primary Prevention Trial Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac - Colorectal Neoplasms | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 354 | 2013-08-23 | 2026-10-23 |
| Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer Sulindac, Placebo, Validate assays and shipping methods - Colorectal Cancer, Liver Metastasis | Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2013-04-01 | 2015-10-23 |
| NSAID Effects on Clinical and Imaging Breast Biomarkers Sulindac - Inflammation, Cancer | Phase 2 | Completed | Stony Brook University | 114 | 2012-12-01 | 2023-02-10 |
| A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine plus Sulindac, Eflornithine plus Placebo, Sulindac plus Placebo - Familial Adenomatous Polyposis | Phase 3 | Withdrawn | Cancer Prevention Pharmaceuticals, Inc. | 2011-03-01 | 2015-04-24 | |
| A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Erlotinib, Sulindac, Placebo A - Adenomatous Polyposis Coli | Phase 2 | Completed | University of Utah | 92 | 2010-04-01 | 2016-06-17 |
| Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma sulindac, placebo, laboratory biomarker analysis - Precancerous Condition | Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2009-02-01 | 2017-12-26 |
| Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma epirubicin hydrochloride, sulindac, immunologic technique - Melanoma (Skin) | Phase 2 | Completed | Cancer Trials Ireland | 32 | 2007-08-01 | 2014-12-31 |
| Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck Bevacizumab, erlotinib, Sulindac - Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Terminated | Massachusetts General Hospital | 36 | 2006-10-01 | 2017-04-13 |
| Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia sulindac, placebo - Precancerous Condition, Stage I Non-small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 61 | 2006-08-01 | 2014-05-23 |
| Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis Sulindac (drug), VSL#3 (probiotic), Inulin (probiotic) - Adenomatous Polyposis Coli | Phase 2 | Unknown | Radboud University Medical Center | 30 | 2006-04-01 | 2007-08-10 |
| Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers sulindac, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Not applicable | Completed | Mayo Clinic | 28 | 2006-04-01 | 2015-04-28 |
| Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia oligofructose-enriched inulin, sulindac, placebo - Colon Cancer, Precancerous Condition | Phase 2 | Completed | National Cancer Institute (NCI) | 85 | 2006-03-01 | 2017-02-15 |
| A Randomized Study of Sulindac in Oral Premalignant Lesions sulindac, Placebo - Leukoplakia, Oral, Benign Neoplasms | Not applicable | Completed | Memorial Sloan Kettering Cancer Center | 63 | 2006-02-23 | 2020-11-19 |
| Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer sulindac, laboratory biomarker analysis - Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2005-11-01 | 2013-05-03 |
Showing 20 of 27. Sign in to see all of them.
Adenomatous Polyposis Coli (4) · Breast Neoplasms (4) · Colorectal Neoplasms (4) · Precancerous Conditions (4) · Colonic Neoplasms (3) · Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (2) · Aberrant Crypt Foci (1) · Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Polyps (1) · Coproporphyria (1) · Desmoid Tumors (1) · Fragile X Syndrome (1)
National Cancer Institute (NCI) (6) · Cancer Prevention Pharmaceuticals, Inc. (3) · Massachusetts General Hospital (2) · University of Medicine and Dentistry of New Jersey (2) · Alison Stopeck (1) · Cancer Trials Ireland (1) · Children's Oncology Group (1) · Duke University (1) · Fox Chase Cancer Center (1) · Healx Limited (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Radboud University Medical Center (1) · SWOG Cancer Research Network (1)
United States (23) · Canada (2) · Netherlands (2) · Australia (1) · Belgium (1) · Germany (1) · India (1) · Ireland (1) · Spain (1) · United Kingdom (1)
Alfred M. Cohen, M.D. (1) · Alison S Stopeck, MD (1) · Alison Stopeck, MD (1) · Amir Fathi, MD (1) · Carol Burke, M.D. (1) · Elizabeth Berry-Kravis (1) · Fokko M Nagengast, PhD (1) · Frank Meyskens (1) · James Church, M.D. (1) · James Jett (1) · Jason A. Zell, D.O., MPH (1) · Jay O. Boyle, M.D. (1) · Jennifer Grandis, MD (1)
PMID 20538001, PMID 23261228, PMID 27002448, PMID 29423501, PMID 30012100, PMID 32905675, PMID 34112707, PMID 34261858, PMID 35039952
N01CN35000 (2), P30CA015083 (2), P30CA023074 (2), N01CN35158 (1), P01CA073992 (1), P30CA006927 (1), P30CA016056 (1), P30CA016672 (1), R01CA088078 (1), R01CA235677 (1), U10CA037429 (1), U10CA098543 (1)